Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AEON Biopharma, Inc. (AEON)

AEON Biopharma says FDA feedback clarifies ABP-450 biosimilar development path

Neutral Impact 3 of 5 legal/regulatory Written later

AEON Biopharma received official minutes from its FDA Type 2b meeting on the development path for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with the company's two-stage pharmacodynamic study design and said previously completed Daewoong comparative studies may be submitted as supportive evidence, while the company will not start a standalone comparative efficacy study for now. The filing also says the Two-Year Milestone Warrants will expire on November 16, 2026, which affects warrant holders.

Key points

  • FDA agreed in principle with the two-stage CMAP pharmacodynamic study design; company expects to file an IND in Q4 2026 and start the study in Q1 2027
  • Previously completed Daewoong comparative studies may be considered as supportive evidence, subject to scientific bridging
  • No standalone comparative efficacy study planned at this time; company plans to return to the FDA in 2027
  • Two-Year Milestone Warrants will expire on November 16, 2026, unless exercised before that date

The filing

CompanyAEON Biopharma, Inc. (AEON)
Form8-K, current report
Filed with the SECSep 30, 2026, 8:00 AM ET
Accession number0001837607-26-000064

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.